Trial Registration, Protocol Transparency, and Results Disclosure in Phase 2

Published on 25/12/2025

Ensuring Transparency in Phase 2: Trial Registration, Protocol Disclosure, and Public Reporting

Table of Contents

Introduction

In today’s regulatory and public environment, transparency in clinical trials is not optional—it is mandatory. Phase 2 trials must be registered on public platforms, key elements of their protocols disclosed, and results reported in accordance with national and international laws. Sponsors that fail to meet these requirements risk reputational damage, publication rejection, and regulatory penalties. This tutorial outlines the steps and standards for trial registration, protocol transparency, and results disclosure during Phase 2 clinical research.

Why Transparency Matters in Phase 2

Builds public trust: Enhances accountability and scientific integrity
Prevents duplication: Publicly available trials reduce unnecessary subject exposure
Supports publication: Major journals require registration and protocol availability
Meets legal and regulatory obligations: U.S. FDAAA, EU Clinical Trials Regulation, WHO Joint Statement

Trial Registration Requirements

1. ClinicalTrials.gov (U.S.)

Mandated under FDAAA 801 for any applicable clinical trial of a drug, biologic, or device
Must be registered within 21 days of enrolling the first participant
Registration must include:
- Study title, condition, and intervention
- Eligibility criteria
- Enrollment and study dates
- Primary and secondary outcomes

2. EU Clinical Trials Register (EUCTR)

Mandatory for all interventional trials conducted in the EU/EEA
All protocol versions and substantial amendments must

be submitted

3. CTRI (India)

All trials in India must be prospectively registered on the Clinical Trials Registry of India
Sponsored and investigator-initiated trials are equally required to register

4. Japic/UMIN (Japan)

PMDA encourages registration on Japan’s UMIN-CTR or Japic CTI
Part of ICMJE-compliant registries

Protocol Transparency and Public Disclosure

Publishing study protocols improves credibility and allows reproducibility
Many journals and WHO recommend uploading full protocols as supplementary materials
Platforms like ClinicalTrials.gov and EU CTIS now allow protocol uploads

Results Disclosure Requirements

FDAAA 801 (United States)

Applicable trials must submit results to ClinicalTrials.gov within 12 months of primary completion
Includes participant flow, demographics, outcome measures, and adverse events
Noncompliance may result in up to $13,000/day in fines and public notices

EU Clinical Trials Regulation

Results must be posted within 12 months of study completion
Layperson summary required in plain language for public use

WHO Expectations

World Health Organization expects public posting of summary results for all interventional trials
Strongly encourages posting of anonymized individual patient data (IPD) where feasible

Best Practices for Trial Transparency

Register all Phase 2 trials prospectively before first patient enrollment
Use plain, non-promotional language in public fields
Pre-specify and match outcome measures between protocol and registry
Prepare lay summaries that are scientifically accurate and easy to understand
Keep registration entries updated throughout the study

Publishing Requirements and ICMJE Compliance

Top journals (e.g., NEJM, Lancet, JAMA) require ICMJE-compliant registration for publication
Failure to register may lead to manuscript rejection regardless of quality
Retrospective registration is generally not accepted

Ethical and Public Health Considerations

Transparency contributes to better policy, meta-analyses, and treatment access
Respects participant rights by making trial outcomes available
Prevents selective outcome reporting and publication bias

Technology Platforms for Disclosure

ClinicalTrials.gov – U.S. public trial registry and result database
EudraCT/EU-CTIS – European Clinical Trials Information System
CTRI – Clinical Trials Registry of India
Vivli, TransCelerate – Data sharing platforms for IPD

Conclusion

Trial registration, protocol disclosure, and public results reporting are now integral parts of the clinical research lifecycle. For Phase 2 trials, transparency not only meets legal obligations but also builds trust, improves trial design, and increases scientific value. By following international standards and registry-specific rules, sponsors can ensure compliance while contributing meaningfully to global health and evidence-based medicine.